Inserm's tech transfer office generated a $60.4m turnover during 2019, the year that saw Pfizer acquire its biotech spinout Therachon for at least $340m.
Inserm Transfert, the tech transfer subsidiary for France-based research institute Inserm, has announced its spinouts collectively raised €188m ($221m) during the 2019 financial year.
Revenues at the TTO amounted to $60.4m, of which $35.1m came from industry partnership agreements.
Inserm Transfert’s biggest exit came when pharmaceutical Pfizer paid up to $810m for its rare genetic disorder drug spinout Therachon in May 2019, supplying $340m of the cash upfront.
Inserm Transfert generated eight new spinouts during 2019 and currently has 57 pre-maturation or maturation-stage projects, 35 of which are eligible for proof-of-concept during 2020.
The combined portfolio raised $1.8m from Inserm to support concept validation, and the institute reported a total of 91 biotech patents, up from 70 in the previous year.
Inserm Transfert says it secured $25.3m of grant funding for 11 national and European-level collaborations, including seven programs launched with EU research and innovation scheme Horizon 2020.
